基于结构的RIPK1强效和选择性的II型激酶抑制剂的开发
Ying Qin1,2, Dekang Li1,2, Chunting Qi1
1Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China.
Acta pharmaceutica Sinica. B
|January 23, 2024
概括
研究人员开发了一种新的II型RIPK1抑制剂,化合物62,在炎症疾病模型中显示出强烈的疗效. 这种强效和选择性抑制剂为进一步研究和针对RIPK1.1的药物开发提供了有价值的工具.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 受体相互作用的氨酸/氨酸蛋白激酶1 (RIPK1) 是炎症和细胞死亡的关键调节者.
- RIPK1活动的失调与各种炎症和退行性疾病有关.
- 现有的全性RIPK1抑制剂 (RIPK1i) 正在进入临床试验,新兴的选择性抑制剂针对多个部位.
研究的目的:
- 理性地开发一系列新的II型RIPK1抑制剂.
- 为了优化化合物的效力,选择性和口服生物利用性.
- 在炎症性疾病的临床前模型中评估开发的抑制剂的疗效.
主要方法:
- 结构引导药物设计和优化.
- 重新发现和重新评估之前报告的RIPK3抑制剂的机制.
- 在急性和慢性炎症疾病的小鼠模型中的体内疗效研究.
主要成果:
- 开发了一系列新型II型RIPK1抑制剂.
- 鉴定和优化化合物62,一种强效,选择性,口服可生物利用的RIPK1抑制剂.
- 在炎症性疾病的小鼠模型中证明62化合物的非凡有效性.
结论:
- 化合物62是研究RIPK1在动物疾病模型中的宝贵工具.
- 开发的RIPK1抑制剂代表了未来在炎症条件下治疗发展的有希望的线索.
- 用选择性抑制剂向RIPK1为治疗炎症和退行性疾病提供了可行的策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Receptor Tyrosine Kinases
12.9K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K


